Cinase is commonly used to provide continuous, long-term support for managing conditions involving inflammatory or irritative processes in the respiratory system, addressing both chronic lower airway and nasal symptoms. The medicine plays a role in managing these conditions, which may assist with easing the overall symptom burden during periods of heightened symptoms. It is relevant for managing symptoms related to allergic rhinitis and asthma.

---

Supportive Management of Respiratory Inflammation

The medication is relevant for easing symptomatic discomfort across two primary domains: persistent asthma and allergic rhinitis, which includes both seasonal and perennial manifestations. The therapeutic benefit helps address symptoms related to inflammatory or irritative states, thereby contributing to easing symptoms associated with flare-ups and assists with maintaining functional stability for improved comfort during symptomatic periods. This prophylactic support is considered relevant across key patient groups, including adults, adolescents, and children (based on specific age and indication).

“It is commonly used to help with groups of symptoms that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.”

---

Quick Fact: Management of Pronounced Nasal and Airway Symptoms

This medicine is applied when clusters of symptoms like pronounced nasal congestion, noticeable runny nose, sneezing, and recurrent wheezing require additional symptomatic support, and may assist with maintaining functional stability in chronic conditions.

Regulatory References

1. Ciclesonide Nasal Spray: MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Cinase — official regulatory information

---

Eligibility scope

Populations for whom use is allowed (as stated in label):

• Adults, adolescents, and pediatric patients 6 years of age and older with Hereditary Angioedema (HAE) for routine prophylaxis.

Populations for whom use is contraindicated:

• Patients who have experienced life-threatening immediate hypersensitivity reactions, including anaphylaxis, to this product (C1 Esterase Inhibitor [Human]).

Age-related eligibility rules:

• Use is established for patients ge 6 years of age.
• Children under 6 years of age are outside the established eligible population for this routine prophylactic use.

Condition-specific eligibility rules & Restrictions:

• Use is restricted to patients with a confirmed diagnosis of Hereditary Angioedema (HAE).
• Patients with underlying risk factors for thromboembolic events (e.g., history of blood clots, indwelling access devices, certain hormone use, immobility) require special consideration and close monitoring.

The regulatory profile defines that Cinase is strictly approved for the prevention of HAE attacks in specific age groups. The principal restriction is the formal contraindication for individuals who have a history of severe allergic reactions to the drug. Beyond this, the official labeling mandates special consideration and monitoring for patients who present with risk factors for developing blood clots. This information establishes the regulatory boundaries for who can safely use the medicine for its indicated purpose.

Interactions with other medicines and products

Cinase (Ciclesonide) has officially documented interaction patterns primarily involving metabolic pathways and additive pharmacodynamic effects, as detailed in regulatory prescribing information.

Pharmacokinetic Interactions

Interaction Type	Substance Category	Official Interaction Outcome
Metabolic Inhibition	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)	Co-administration results in a clinically significant increase in the systemic exposure of the active metabolite, Des-ciclesonide. Regulatory data show that co-administration with Ketoconazole increases the active metabolite's AUC by approximately 3.5-fold.
Metabolic Induction	Strong CYP3A4 Inducers (e.g., Apalutamide)	Co-administration may decrease the plasma levels of the active metabolite.

---

Pharmacodynamic and Population Interactions

Interaction Type	Substance or Condition	Official Interaction Outcome
Additive Effect	Other Corticosteroids (Oral, Inhaled)	Increases the risk of systemic glucocorticoid effects (e.g., adrenal suppression).
Pharmacodynamic Risk	Desmopressin	Potential for increased risk of hyponatremia (low sodium levels).
Population Note	Hepatic Impairment	Systemic exposure of the active metabolite is increased (up to 2.7-fold) in patients with liver impairment compared to healthy subjects.

No mandatory timing separation rules are explicitly documented in official regulatory labeling. Furthermore, no specific pharmacokinetic or pharmacodynamic interactions with food, alcohol, or herbal products are formally documented.

How Cinase Works: The Mechanistic Blueprint

Ciclesonide is delivered as an inactive prodrug that undergoes rapid enzymatic conversion by esterase enzymes within the respiratory lining into its active metabolite, des-ciclesonide. This localized process of bioactivation ensures the active compound is primarily concentrated at the target tissue where it forms a temporary tissue reservoir by conjugating with local fatty acids. The active metabolite acts as a Glucocorticoid Receptor Agonist, initiating a genomic cascade inside the cell nucleus.

This genomic action directly downregulates the transcription of genes encoding pro-inflammatory signals (e.g., cytokines) and upregulates anti-inflammatory proteins, such as Lipocortin-1. The resultant Lipocortin-1 indirectly inhibits the activity of Phospholipase A2 ( PLA2), thereby reducing the synthesis of inflammatory mediators including prostaglandins and leukotrienes. The suppression of inflammatory sources results in physiological consequences: a reduction in mucosal edema (swelling), decreased cellular infiltration, and less mucus hypersecretion, contributing to the regulation of airway lumen dimension.

Administration Instructions for Cinase

The use of Cinase involves specific dosages, administration routes, and schedules. Cinase is administered via subcutaneous injection or intravenous (IV) infusion.

Dosage and Schedule

Administration typically follows a distinct loading phase of weekly doses, followed by a maintenance phase of less frequent, periodic doses. Dosing varies based on the patient's age, weight, and the specific condition being treated, and may utilize a loading dose or a non-loading dose regimen:

• Adult Subcutaneous Dosage: A common regimen is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. In certain circumstances, a 150 mg dose may be used.
• Adult Intravenous Dosage: The maintenance phase is typically 1.75 mg/kg every 4 weeks (with a maximum maintenance dose of 300 mg per infusion). A loading dose of 6 mg/kg at Week 0 may precede the maintenance dose.
• Pediatric Subcutaneous Dosage: For children aged 6 years and older, dosing is weight-based. For patients weighing less than 50 kg, the dose is 75 mg; for patients weighing 50 kg or more, the dose is 150 mg. This is administered at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks thereafter.

Preparation and Procedural Rules

Cinase is supplied in prefilled pens, prefilled syringes for subcutaneous use, and single-dose vials for IV infusion. IV preparations require specific procedures for dilution and mixing, and the maximum infusion rate is observed. The medicine is not explicitly linked to meal consumption. If a scheduled IV dose is varied (e.g., within a 7-day window), subsequent doses are administered according to the original dosing schedule.

Research Evidence / Overview of Studies for Cinase

---

Evidence for Use in Persistent Asthma

The research base for Cinase in persistent asthma relies heavily on short-term randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity and applied in studies examining short-term episodic symptom patterns. Outcomes that research examined included standard measures of pulmonary function, such as FEV1, as well as patient-reported outcomes describing perceived discomfort, like asthma symptom scores. Studies monitored physiological strain and stress over defined time intervals, typically 4 to 12 weeks.

Studies reported measurements of values related to lung function measures and the recorded frequency of rescue inhaler use. For people with severe asthma who were also taking oral steroids, specific studies monitored changes related to the oral steroid dose, and the evidence provides insight into short-term changes in this group.

---

Evidence for Use in Allergic Rhinitis

Cinase was also evaluated in numerous placebo-controlled randomized trials for conditions characterized by fluctuating or episodic manifestations, specifically seasonal and perennial allergic rhinitis. Research applied in studies examining patient-reported experiences for outcomes reflecting daily functioning or activity level. Studies explored nasal symptoms like congestion, runny nose, sneezing, and itching, using validated symptom scoring systems to capture phases of heightened symptom activity.

These studies reported measurements of values related to the total nasal symptom scores over periods ranging from a few weeks (for seasonal rhinitis) to as long as one year (in perennial rhinitis safety studies). Studies reported measurements of values related to both nasal symptom scores and health-related quality of life measures.

---

Research Gaps and Uncertainties

While studies up to 52 weeks were conducted, comparative evidence is lacking for long-term outcomes (exceeding one year) against other maintenance treatments. This means there is limited information regarding long-term observational data on measures like the frequency of severe asthma attacks. Additionally, follow-up durations were limited in many initial efficacy trials. Research provides context but not individual predictions, and studies contribute to the broader evidence landscape by highlighting what is known—and what is still uncertain.

Key Studies & References

1. Ciclesonide Nasal Spray: MedlinePlus Drug Information
2. Ciclesonide Inhalation Aerosol: MedlinePlus Drug Information

Common questions about Cinase (FAQ)

Q: What is Cinase and what is it used for?

A: Cinase is the brand name for a prescription medication containing the active ingredient cinacalcet. It belongs to a class of drugs called calcimimetics. Cinacalcet works by mimicking the effect of calcium on the parathyroid gland, which helps reduce the release of parathyroid hormone (PTH).

Cinase is used primarily to treat conditions associated with high levels of PTH and/or calcium in the blood. Specifically, it is approved to treat:

• Secondary hyperparathyroidism (SHPT) in patients with Chronic Kidney Disease (CKD) who are on dialysis.
• Parathyroid carcinoma (cancer of the parathyroid gland).
• Primary hyperparathyroidism in patients who have high blood calcium levels and cannot undergo surgery to remove the parathyroid gland.

Q: How does Cinase work to treat Secondary Hyperparathyroidism?

A: In patients with Chronic Kidney Disease (CKD) on dialysis, the kidneys may not be able to effectively manage calcium and phosphate levels, often leading to a condition called Secondary Hyperparathyroidism (SHPT). In SHPT, the parathyroid glands become overactive and produce too much Parathyroid Hormone (PTH). High PTH levels can lead to bone disease and other health issues.

Cinase (cinacalcet) is a calcimimetic. It works by making the calcium-sensing receptors on the surface of the parathyroid glands more sensitive to the calcium already in the blood. When the receptors are more sensitive, the gland 'thinks' the calcium levels are higher than they actually are. This tricks the overactive parathyroid glands into reducing the production and release of PTH, bringing PTH levels closer to the target range.

Q: What are the most common side effects of Cinase?

A: The most commonly reported side effects when taking Cinase include:

• Nausea and vomiting: These are often the most common side effects, especially when starting treatment.
• Diarrhea
• Muscle pain (myalgia)
• Dizziness
• Loss of appetite

A less common but serious side effect is hypocalcemia (low blood calcium levels). Because Cinase lowers PTH, it can cause calcium levels in the blood to drop too low. Symptoms of severe hypocalcemia can include muscle cramps, twitching, or seizures. Blood calcium levels are typically monitored closely by a healthcare provider while taking this medication.

Q: Can Cinase interact with other medications I am taking?

A: Yes, Cinase can interact with several other medications. It is very important to tell your healthcare provider and pharmacist about all prescription, non-prescription, and herbal supplements you are taking.

Cinase is metabolized by certain liver enzymes (CYP2D6, CYP3A4, CYP1A2). Taking Cinase with drugs that strongly inhibit these enzymes can increase the level of Cinase in the body, potentially increasing the risk of side effects like hypocalcemia. Examples of medications that may interact include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• Strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine)

Additionally, Cinase itself is a strong inhibitor of the enzyme CYP2D6. This means Cinase can increase the levels of other medications metabolized by CYP2D6, such as some anti-depressants (e.g., nortriptyline), anti-arrhythmics (e.g., flecainide), and pain medications (e.g., tramadol). Your doctor may need to adjust the doses of these other medications if you start taking Cinase.

The official regulatory guidelines for storing and disposing of Ciclesonide (Cinase) focus on protecting the product's stability and ensuring public safety.

Storage/Disposal Domain	Official Regulatory Requirement
Temperature & Environment	Store medication at room temperature; Do not freeze and keep away from excess heat and direct light. Inhalation Aerosol canisters must not be exposed to temperatures above 49 C (120 F), as this may cause bursting.
Container Integrity	The medication must be kept in the container it came in, tightly closed. The nasal spray bottle must be discarded 4 months after its initial removal from the foil pouch, regardless of remaining liquid.
Disposal & Safety	Keep the medication out of the sight and reach of children. Unused or expired products must not be thrown into household waste or flushed down the toilet unless explicitly instructed by the pharmacist or label. Canisters must not be punctured or thrown into a fire due to the pressurized contents.